D
Dong Wan Kim
Researcher at Seoul National University Hospital
Publications - 880
Citations - 61091
Dong Wan Kim is an academic researcher from Seoul National University Hospital. The author has contributed to research in topics: Lung cancer & Crizotinib. The author has an hindex of 89, co-authored 833 publications receiving 49632 citations. Previous affiliations of Dong Wan Kim include University of California, Irvine & Korea University.
Papers
More filters
Journal ArticleDOI
Clinical predictors versus epidermal growth factor receptor mutation in gefitinib-treated non-small-cell lung cancer patients.
Sae-Won Han,Tae-You Kim,Kyung-Hun Lee,Pil Gyu Hwang,Yoon Kyung Jeon,Do-Youn Oh,Se-Hoon Lee,Dong Wan Kim,Seock-Ah Im,Doo Hyun Chung,Dae Seog Heo,Yung-Jue Bang +11 more
TL;DR: EGFR mutation should be analyzed whenever possible for effective prediction of objective benefit from gefitinib in NSCLC patients with one or more clinical predictors.
Journal ArticleDOI
Size-controlled synthesis of monodispersed mesoporous α-Alumina spheres by a template-free forced hydrolysis method
Hee Suk Roh,Geun Kyu Choi,Jae Sul An,Chin Moo Cho,Dong Hoe Kim,Ik Jae Park,Tae Hoon Noh,Dong Wan Kim,Kug Sun Hong +8 more
TL;DR: The formation of monodispersed spherical aluminum hydrous oxide precursors with tunable sizes with enhanced specific surface areas is demonstrated by controlling the variables of a forced hydrolysis method.
Journal ArticleDOI
Induction chemotherapy in head and neck squamous cell carcinoma of the paranasal sinus and nasal cavity: a role in organ preservation
Chan Young Ock,Bhumsuk Keam,Tae Min Kim,Doo Hee Han,Tae Bin Won,Se-Hoon Lee,J. Hun Hah,Tack Kyun Kwon,Dong Wan Kim,Dong Young Kim,Chae Seo Rhee,Hong Gyun Wu,Myung-Whun Sung,Dae Seog Heo +13 more
TL;DR: IC could be considered for down-staging patients with advanced T-stage disease and could also be a reasonable option for eyeball preservation in locally advanced HNSCC of the PNSNC.
Journal ArticleDOI
Soluble PD-L1 is a predictive and prognostic biomarker in advanced cancer patients who receive immune checkpoint blockade treatment.
So Yeon Oh,So Yeon Kim,Bhumsuk Keam,Bhumsuk Keam,Tae Min Kim,Tae Min Kim,Dong Wan Kim,Dong Wan Kim,Dae Seog Heo,Dae Seog Heo +9 more
TL;DR: In this paper, the significance of sPD-L1 in cancer patients receiving immune checkpoint inhibitor therapy was investigated, and it was found that high sPDL1 levels were associated with progressive disease and were an independent prognostic factor predicting lower PFS and OS in these patients.
Journal ArticleDOI
In Situ Conversion of Metal–Organic Frameworks into VO2–V3S4 Heterocatalyst Embedded Layered Porous Carbon as an “All-in-One” Host for Lithium–Sulfur Batteries
TL;DR: A layered porous carbon (LPC) with VO2 /V3 S4 heterostructures using one-step carbonization-sulfidation of metal-organic framework templates as a sulfur host that meets all the criteria to realize porous, conductive, and polar functions is reported.